Seven Fleet Capital Management LP acquired a new stake in shares of Entero Therapeutics, Inc. (NASDAQ:ENTO – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 411,065 shares of the company’s stock, valued at approximately $711,000. Seven Fleet Capital Management LP owned 25.89% of Entero Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Virtu Financial LLC purchased a new position in shares of Entero Therapeutics in the third quarter worth $59,000. GSA Capital Partners LLP bought a new stake in Entero Therapeutics during the 2nd quarter valued at $65,000. Persistent Asset Partners Ltd purchased a new stake in Entero Therapeutics during the 2nd quarter valued at $198,000. Elmind Capital LP purchased a new stake in Entero Therapeutics during the 2nd quarter valued at $363,300,000. Finally, ADAR1 Capital Management LLC bought a new stake in Entero Therapeutics in the 2nd quarter worth $3,642,000. Institutional investors own 12.30% of the company’s stock.
Entero Therapeutics Trading Up 11.2%
ENTO stock opened at $4.06 on Thursday. The firm’s 50-day moving average price is $3.82 and its two-hundred day moving average price is $3.42. Entero Therapeutics, Inc. has a 12-month low of $0.32 and a 12-month high of $5.84. The stock has a market capitalization of $6.45 million, a price-to-earnings ratio of -2.40 and a beta of 1.19.
About Entero Therapeutics
Entero Therapeutics, Inc (NASDAQ: ENTO) is a clinical‐stage specialty pharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and debilitating gastrointestinal (GI) disorders. The company leverages targeted delivery technologies designed to localize therapeutic molecules directly to affected regions of the GI tract, aiming to enhance efficacy while minimizing systemic exposure. Entero’s research and development efforts focus on addressing chronic conditions with significant unmet medical needs, including malabsorption syndromes and motility‐related GI diseases.
Entero’s pipeline features multiple lead candidates in varying stages of clinical development.
Read More
- Five stocks we like better than Entero Therapeutics
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for Entero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
